Ad Header



The Pulse of the Pharmaceutical Industry

GlaxoSmithKline CEO Confident Investors Will Be Pleased With Pipeline on Nov. R&D Day

Written by: | | Dated: Wednesday, July 29th, 2015

GlaxoSmithKline Plc shed more light on its pipeline of experimental medicines, giving a glimpse of drugs in earlier stages of development, although analysts remain skeptical about their promise.

Glaxo has 40 drugs in the middle or final stages of clinical trials, Chief Executive Officer Andrew Witty said on Wednesday, and about half may be submitted to regulators or approved by 2020. Investors have been eager to hear more about the U.K. company’s prospects as competitors roll out cancer drugs that trigger the immune system to fight the disease.



Source: BioSpace Featured News

Leave a Reply

Be the First to Comment!


Ad Right Top


Extensive pharmaceutical business

Oct15deand marketing intelligence. If you would like to purchase a back issue, please contact our customer service department at, or call 800-869-6882.

October 2015 Focus: Top 50 Pharma


Ad Right Bottom

Marketing Communications Directory

Marketing Communications Directory

Healthcare Communications Agencies & Marketing Services Directory

Contract Research Directory

Contract Research Directory

Qualified Clinical Research Organizations Directory

Main Navigation
Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.